InvestorsHub Logo
Followers 827
Posts 119492
Boards Moderated 15
Alias Born 09/05/2002

Re: None

Tuesday, 04/23/2019 8:00:15 PM

Tuesday, April 23, 2019 8:00:15 PM

Post# of 750
FDA approves ABBV’s Skyrizi (risankizumab) for psoriasis:

https://finance.yahoo.com/news/abbvie-expands-immunology-portfolio-u-221900007.html

Skyrizi, an IL-23 antagonist, is one of the drugs ABBV is counting on to compensate for lost sales when Humira biosimilars are launched in the US.

Skyrizi is jointly owned by ABBV and B-I. It has received approval in the EU (CHMP recommendation) and Japan.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ABBV News